Market research
ANIX Anixa Biosciences Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 126M
- P/E ratio
- Not available
- Analyst target
- 10
- Dividend yield
- Not available
- Beta
- 0.52
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US03528H1095
- Market cap
- 126M
- P/E ratio
- Not available
- Analyst target
- 10
- Dividend yield
- Not available
- Beta
- 0.52
About
About Anixa Biosciences Inc
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ANIX discussion.
5 years, 4 months ago
Anixa Biosciences, Inc is currently in a long term downtrend where the price is trading 3.2% below its 200 day moving average.
From a valuation standpoint, the stock is 84.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 212.3.
Anixa Biosciences, Inc's total revenue rose by inf% to $512K since the same quarter in the previous year.
Its net income has increased by 14.8% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 39.4% to $-1M since the same quarter in the previous year.
Based on the above factors, Anixa Biosciences, Inc gets an overall score of 4/5.